Semi-Annual Statement Of Cash Flows

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7256194

Concept As at
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2023-03-31
Semi-annual statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
6,183,000,000 JPY
2,724,000,000 JPY
Interest and dividends received
379,000,000 JPY
414,000,000 JPY
Interest paid
-51,000,000 JPY
-41,000,000 JPY
Income taxes paid
-4,026,000,000 JPY
-1,611,000,000 JPY
Net cash provided by (used in) operating activities
2,485,000,000 JPY
1,486,000,000 JPY
Cash flows from investing activities
Purchase of securities
JPY
-500,000,000 JPY
Purchase of property, plant and equipment
-2,960,000,000 JPY
-1,320,000,000 JPY
Proceeds from sale of property, plant and equipment
0 JPY
1,000,000 JPY
Purchase of investment securities
JPY
-352,000,000 JPY
Proceeds from sale of investment securities
252,000,000 JPY
4,230,000,000 JPY
Other, net
-1,125,000,000 JPY
845,000,000 JPY
Net cash provided by (used in) investing activities
-6,124,000,000 JPY
1,706,000,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
3,000,000,000 JPY
JPY
Repayments of long-term borrowings
-4,680,000,000 JPY
-3,138,000,000 JPY
Dividends paid
-1,275,000,000 JPY
-792,000,000 JPY
Net cash provided by (used in) financing activities
-2,956,000,000 JPY
-3,943,000,000 JPY
Other, net
JPY
-22,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
-97,000,000 JPY
-15,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-6,692,000,000 JPY
-766,000,000 JPY
Cash and cash equivalents
10,603,000,000 JPY
16,738,000,000 JPY
17,505,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.